A simple and reproducible breast cancer prognostic test

Luigi Marchionni, Bahman Afsari, Donald Geman, Jeffrey T. Leek

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Background: A small number of prognostic and predictive tests based on gene expression are currently offered as reference laboratory tests. In contrast to such success stories, a number of flaws and errors have recently been identified in other genomic-based predictors and the success rate for developing clinically useful genomic signatures is low. These errors have led to widespread concerns about the protocols for conducting and reporting of computational research. As a result, a need has emerged for a template for reproducible development of genomic signatures that incorporates full transparency, data sharing and statistical robustness. Results: Here we present the first fully reproducible analysis of the data used to train and test MammaPrint, an FDA-cleared prognostic test for breast cancer based on a 70-gene expression signature. We provide all the software and documentation necessary for researchers to build and evaluate genomic classifiers based on these data. As an example of the utility of this reproducible research resource, we develop a simple prognostic classifier that uses only 16 genes from the MammaPrint signature and is equally accurate in predicting 5-year disease free survival. Conclusions: Our study provides a prototypic example for reproducible development of computational algorithms for learning prognostic biomarkers in the era of personalized medicine.

Original languageEnglish (US)
Article number336
JournalBMC genomics
Volume14
Issue number1
DOIs
StatePublished - May 17 2013

Keywords

  • Biomarkers
  • Breast cancer
  • Gene expression analysis
  • Genomics
  • MammaPrint
  • Personalized medicine
  • Prediction
  • Reproducible research
  • Top scoring pair

ASJC Scopus subject areas

  • Biotechnology
  • Genetics

Fingerprint

Dive into the research topics of 'A simple and reproducible breast cancer prognostic test'. Together they form a unique fingerprint.

Cite this